Which medications in the drug class Dopamine Agonists are used in the treatment of Pediatric Sleep Disorders?

Updated: Oct 09, 2018
  • Author: Sufen Chiu, MD, PhD; Chief Editor: Caroly Pataki, MD  more...
  • Print

Dopamine Agonists

Preliminary efficacious results for treatment using these agents have been noted in youths with restless legs syndrome (RLS) and periodic limb movement during sleep (PLMS). Findings are based on nonrandomized non–placebo-controlled study.

Pergolide was withdrawn from the US market on March 29, 2007, because of heart valve damage resulting in cardiac valve regurgitation. Do not abruptly stop pergolide. Health care professionals should assess patients’ need for dopamine agonist therapy and consider alternative treatment. If continued treatment with a dopamine agonist is needed, another such agent should be substituted for pergolide. For more information, see FDA MedWatch Product Safety Alert and Medscape Alerts: Pergolide Withdrawn From US Market.

Pergolide (Permax)

Withdrawn from US market. Pergolide is not FDA-approved for RLS or PLMS. It is a potent and long-acting dopamine agonist that reduces tonic stimulation of dopaminergic D2 receptors located on intrastriatal cholinergic neurons.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!